938 related articles for article (PubMed ID: 19826053)
1. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism.
Tamura K; Makino A; Hullin-Matsuda F; Kobayashi T; Furihata M; Chung S; Ashida S; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2009 Oct; 69(20):8133-40. PubMed ID: 19826053
[TBL] [Abstract][Full Text] [Related]
2. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
Pizer ES; Pflug BR; Bova GS; Han WF; Udan MS; Nelson JB
Prostate; 2001 May; 47(2):102-10. PubMed ID: 11340632
[TBL] [Abstract][Full Text] [Related]
3. Increased lipogenesis in steroid-responsive cancer cells: mechanisms of regulation, role in cancer cell biology and perspectives on clinical applications.
Swinnen JV
Verh K Acad Geneeskd Belg; 2001; 63(4):321-33. PubMed ID: 11603058
[TBL] [Abstract][Full Text] [Related]
4. Androgens, lipogenesis and prostate cancer.
Swinnen JV; Heemers H; van de Sande T; de Schrijver E; Brusselmans K; Heyns W; Verhoeven G
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):273-9. PubMed ID: 15663990
[TBL] [Abstract][Full Text] [Related]
5. [Androgens and increased lipogenesis in prostate cancer. Cell biologic and clinical perspectives].
Verhoeven G
Verh K Acad Geneeskd Belg; 2002; 64(3):189-95; discussion 195-6. PubMed ID: 12238242
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer.
Rossi S; Graner E; Febbo P; Weinstein L; Bhattacharya N; Onody T; Bubley G; Balk S; Loda M
Mol Cancer Res; 2003 Aug; 1(10):707-15. PubMed ID: 12939396
[TBL] [Abstract][Full Text] [Related]
7. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.
Lee MY; Moon JS; Park SW; Koh YK; Ahn YH; Kim KS
Biochem J; 2009 Jan; 417(1):313-22. PubMed ID: 18774944
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1.
Amler LC; Agus DB; LeDuc C; Sapinoso ML; Fox WD; Kern S; Lee D; Wang V; Leysens M; Higgins B; Martin J; Gerald W; Dracopoli N; Cordon-Cardo C; Scher HI; Hampton GM
Cancer Res; 2000 Nov; 60(21):6134-41. PubMed ID: 11085537
[TBL] [Abstract][Full Text] [Related]
9. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
Tamura K; Furihata M; Tsunoda T; Ashida S; Takata R; Obara W; Yoshioka H; Daigo Y; Nasu Y; Kumon H; Konaka H; Namiki M; Tozawa K; Kohri K; Tanji N; Yokoyama M; Shimazui T; Akaza H; Mizutani Y; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Cancer Res; 2007 Jun; 67(11):5117-25. PubMed ID: 17545589
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
[TBL] [Abstract][Full Text] [Related]
11. Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells.
Sinha R; Pinto JT; Facompre N; Kilheffer J; Baatz JE; El-Bayoumy K
Nutr Cancer; 2008; 60(2):267-75. PubMed ID: 18444160
[TBL] [Abstract][Full Text] [Related]
12. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.
Locke JA; Guns ES; Lubik AA; Adomat HH; Hendy SC; Wood CA; Ettinger SL; Gleave ME; Nelson CC
Cancer Res; 2008 Aug; 68(15):6407-15. PubMed ID: 18676866
[TBL] [Abstract][Full Text] [Related]
13. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.
Uemura M; Tamura K; Chung S; Honma S; Okuyama A; Nakamura Y; Nakagawa H
Cancer Sci; 2008 Jan; 99(1):81-6. PubMed ID: 17986282
[TBL] [Abstract][Full Text] [Related]
14. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
Leon CG; Locke JA; Adomat HH; Etinger SL; Twiddy AL; Neumann RD; Nelson CC; Guns ES; Wasan KM
Prostate; 2010 Mar; 70(4):390-400. PubMed ID: 19866465
[TBL] [Abstract][Full Text] [Related]
15. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
16. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth.
Takayama K; Tsutsumi S; Suzuki T; Horie-Inoue K; Ikeda K; Kaneshiro K; Fujimura T; Kumagai J; Urano T; Sakaki Y; Shirahige K; Sasano H; Takahashi S; Kitamura T; Ouchi Y; Aburatani H; Inoue S
Cancer Res; 2009 Jan; 69(1):137-42. PubMed ID: 19117996
[TBL] [Abstract][Full Text] [Related]
17. Reg IV: a promising marker of hormone refractory metastatic prostate cancer.
Gu Z; Rubin MA; Yang Y; Deprimo SE; Zhao H; Horvath S; Brooks JD; Loda M; Reiter RE
Clin Cancer Res; 2005 Mar; 11(6):2237-43. PubMed ID: 15788672
[TBL] [Abstract][Full Text] [Related]
18. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET.
Anazawa Y; Nakagawa H; Furihara M; Ashida S; Tamura K; Yoshioka H; Shuin T; Fujioka T; Katagiri T; Nakamura Y
Cancer Res; 2005 Jun; 65(11):4578-86. PubMed ID: 15930275
[TBL] [Abstract][Full Text] [Related]
19. Analysis of androgen-induced increase in lipid accumulation in prostate cancer cells.
Sikkeland J; Lindstad T; Saatcioglu F
Methods Mol Biol; 2011; 776():371-82. PubMed ID: 21796538
[TBL] [Abstract][Full Text] [Related]
20. Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events.
Sirotnak FM; She Y; Khokhar NZ; Hayes P; Gerald W; Scher HI
Mol Carcinog; 2004 Nov; 41(3):150-63. PubMed ID: 15390081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
